PGNY
Progyny, Inc.26.01
-0.33-1.25%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.24BP/E (TTM)
41.95Basic EPS (TTM)
0.62Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Progyny's Q2 revenue climbed 9% year-over-year to $332.9M, driven by 11% growth in fertility benefits and 8% in pharmacy services, while gross margin expanded 1.2 points to 23.7% on care management efficiencies. Operating income rose 18% to $24.4M, with diluted EPS up 12% to $0.19, reconciling cleanly to 89.6M shares. Free cash flow hit $97.2M for the half-year on $105.3M operating cash minus $8.1M capex, bolstering $132.5M cash and $172.6M marketable securities; a $200M revolver closed July 1 with no draws. The January acquisition of Benefit Bump for $10.5M added $4.4M goodwill and $5.3M intangibles over 5 years, eyeing family support synergies. Yet competition in fertility benefits could squeeze margins if rivals undercut pricing.
8-K
Progyny boosts Q2 revenue, raises guidance
Progyny reported Q2 2025 revenue of $332.9 million, up 9.5% from last year, driven by more clients and covered lives despite a major client's non-renewal; excluding that client's $17.2 million contribution, growth hit 18%. Gross margin expanded to 23.7%, boosting Adjusted EBITDA to $57.9 million, while operating cash flow reached $55.5 million. The company raised full-year revenue guidance to $1.235-$1.270 billion, citing stronger member engagement. Early sales commitments match last year, but demographic shifts pose normalization risks.
8-K
Progyny announces a new $200M credit facility and positive Q2 outlook.
Progyny, Inc. has entered into a $200 million revolving credit facility maturing in 2030 to enhance operational and financial flexibility. The facility is undrawn with no planned use. The company expects Q2 2025 financial results to slightly exceed prior guidance, with revenue, Adjusted net income, and Adjusted EBITDA anticipated to be slightly above the ranges provided in May. Q2 results will be reported on August 7, 2025.
8-K
Stockholders reject exec pay
Progyny stockholders convened their 2025 Annual Meeting on May 22, electing all three Class III director nominees—Norman Payson, M.D., Debra Morris, and Elizabeth Bierbower—to serve until 2028, while ratifying Ernst & Young LLP as auditors for the fiscal year ending December 31, 2025. Yet, the advisory vote rejected executive compensation, with 43.9 million votes against versus 24.4 million for. This non-binding rebuke signals investor discontent amid strong turnout of 88.39% of shares.
10-Q
Q1 FY2025 results
Progyny posted solid Q1 FY2025 results, with revenue climbing 17% year-over-year to $324.0M, fueled by 22% growth in fertility benefits to $206.4M and 9% in pharmacy benefits to $117.6M, while gross margin edged up to 23.4% from 22.4% on care management efficiencies. Operating income rose 30% to $24.2M, yet net income dipped to $15.1M from $16.9M as taxes doubled to $11.5M on higher profits and less equity comp relief; diluted EPS held steady at $0.17 on 89.3M shares. Cash from operations hit $49.8M, up from $25.7M, though free cash flow wasn't disclosed in the 10-Q; quarter-end cash stood at $109.2M with $146.9M in marketable securities. The January acquisition of Benefit Bump for $10.5M (cash, $2.5M escrowed) added $4.1M to goodwill, bolstering family support offerings. Still, reliance on tech clients poses risks if sector layoffs persist.
CNC
Centene Corporation
38.97-1.48
CVS
CVS Health Corporation
78.29-1.40
ELV
Elevance Health, Inc.
351.90-8.77
FEMY
Femasys Inc.
0.85-0.01
MOH
Molina Healthcare Inc
160.88-5.62
NEUE
NeueHealth, Inc.
6.75+0.00
NIVF
NewGenIvf Group Limited
0.91-0.03
OGN
Organon & Co.
6.97-0.05
OSCR
Oscar Health, Inc.
15.71-0.43
UNH
UnitedHealth Group Incorporated
334.20-6.90